ARCA biopharma, Inc. (ABIO) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Westminster, CO, 미국. 현재 CEO는 Thomas A. Keuer.
ABIO 을(를) 보유 IPO 날짜 1997-08-08, 3 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $34.82M.
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
